{
  "docId": "019de077-0f5f-77ef-a5cf-60b15fd5a5a5",
  "docSlug": "f1a62332dbdfff6b54feb25498e49e7e",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 29,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a line chart to show weight loss over 22 days, highlighting that IV-Docetaxel causes significant weight loss (toxicity) while oral LNC-Docetaxel maintains weight similar to control.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0f5f-77ef-a5cf-60b15fd5a5a5/25",
  "deckHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5",
  "deckJsonHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5.json",
  "deckAnchorHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.54,
        "y": 0.36
      },
      "kind": "callout",
      "text": "KEY TAKEAWAYS",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8a95a9e-4553-43dd-bca4-d8715df486c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.06,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Line chart showing % change in body weight over 22 days for Control, LNC Docetaxel, and IV Docetaxel groups.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5873c59d-49ab-4cca-bbaa-c6977c27a475",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.54,
        "y": 0.4
      },
      "kind": "list",
      "text": "Through Day 22, the total amount of docetaxel administered with oral LNC-docetaxel was more than 8x greater than with IV-docetaxel. Mice treated with oral LNC-docetaxel maintained their body weight; statistically no different than controls. All mice treated with IV-docetaxel lost a significant amount of weight (toxicity)—an average peak loss of 20%. The daily administered oral LNC-docetaxel dose was 50% higher (total administered drug 3.5x greater) than the LNC-docetaxel dose administered in the previous melanoma study.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16acc211-a178-4f81-8691-149f5d244f6d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.65,
        "y": 0.18
      },
      "kind": "source-note",
      "text": "Healthy C57BL/6 mice (n = 24). Oral saline (control), Docetaxel 0.6 mg/mouse iv q week x 3, Oral LNC-docetaxel 0.75 mg/mouse daily through day 22",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10f01a02-7124-4f23-a4b6-4db637beade4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oral LNC Docetaxel Markedly Reduces Toxicity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27814109-b585-44d6-b8fd-ecd142d6a0b5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "1dc7c8af-90c7-432f-97fb-f7b57238aea9",
      "evidence": "The slide shows a comparison of the effects of oral LNC docetaxel versus IV docetaxel on body weight and tumor volume.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 29,
      "from": 15,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "c020a8cd-19c2-4f66-b8fd-1a6de00826c3",
      "evidence": "The regulatory and development strategy for MAT2203 and the LNC platform are presented",
      "position": 2,
      "objective": "What are the near-term milestones and potential for growth?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}